RAD51 and head and neck squamous cell carcinoma: Another study reported that the combination of adavosertib (AZD1775) and a Rad51 inhibitor (B02) significantly inhibited tumor growth in a xenograft mouse model carrying HPV-positive HNSCC, compared to HPV-negative HNSCC (124).